326 related articles for article (PubMed ID: 34538575)
1. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
2. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
3. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
4. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
5.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
6. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
7. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
8. Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.
Künkele A; Brown C; Beebe A; Mgebroff S; Johnson AJ; Taraseviciute A; Rolczynski LS; Chang CA; Finney OC; Park JR; Jensen MC
Biol Blood Marrow Transplant; 2019 Feb; 25(2):223-232. PubMed ID: 30315942
[TBL] [Abstract][Full Text] [Related]
9. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
[TBL] [Abstract][Full Text] [Related]
10. Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells.
Kim-Hoehamer YI; Riberdy JM; Zheng F; Park JJ; Shang N; Métais JY; Lockey T; Willis C; Akel S; Moore J; Meagher MM; Velasquez MP; Triplett BM; Talleur AC; Gottschalk S; Zhou S
Gene Ther; 2023 Apr; 30(3-4):222-231. PubMed ID: 34997202
[TBL] [Abstract][Full Text] [Related]
11. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
12. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
[TBL] [Abstract][Full Text] [Related]
13. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
[TBL] [Abstract][Full Text] [Related]
14. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
[TBL] [Abstract][Full Text] [Related]
15. Automated, scaled, transposon-based production of CAR T cells.
Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
[TBL] [Abstract][Full Text] [Related]
16. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
17. Induction of a central memory and stem cell memory phenotype in functionally active CD4
Blaeschke F; Stenger D; Kaeuferle T; Willier S; Lotfi R; Kaiser AD; Assenmacher M; Döring M; Feucht J; Feuchtinger T
Cancer Immunol Immunother; 2018 Jul; 67(7):1053-1066. PubMed ID: 29605883
[TBL] [Abstract][Full Text] [Related]
18. Simplified process for the production of anti-CD19-CAR-engineered T cells.
Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
[TBL] [Abstract][Full Text] [Related]
19. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.
Jackson Z; Roe A; Sharma AA; Lopes FBTP; Talla A; Kleinsorge-Block S; Zamborsky K; Schiavone J; Manjappa S; Schauner R; Lee G; Liu R; Caimi PF; Xiong Y; Krueger W; Worden A; Kadan M; Schneider D; Orentas R; Dropulic B; Sekaly RP; de Lima M; Wald DN; Reese JS
Front Immunol; 2020; 11():1941. PubMed ID: 32849651
[TBL] [Abstract][Full Text] [Related]
20. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.
Pecher AC; Hensen L; Klein R; Schairer R; Lutz K; Atar D; Seitz C; Stanger A; Schneider J; Braun C; Schmidt M; Horger M; Bornemann A; Faul C; Bethge W; Henes J; Lengerke C
JAMA; 2023 Jun; 329(24):2154-2162. PubMed ID: 37367976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
